Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers

British Journal of Clinical Pharmacology

Volumn 42, Issue 2, 1996, Pages 246-248

  Davis, J D ^a   Dixon, R ^b,c   Khan, A Z ^a   Toon, S ^a   Rolan, P E ^a   Posner, J ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Atovaquone; Drug interactions; Pharmacokinetics; Phenytoin

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; ATOVAQUONE; DRUG METABOLITE; PHENYTOIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030036959     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.40518.x     Document Type: Article

References (12)

1. Hudson AT, Randell AW, Fry M, et al. Novel antimalarial naphthoquinones with potent broad spectrum antiprotozoal activity. Parasitol 1985; 90: 45-55.
2. Fry M, Pudney M. Site of action of the antimalarial hydroxy naphthoquinone, 2-trans[4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 1992; 43: 1545-1553.
3. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993; 328: 1521-1527.
4. Spencer CM, Goa KL. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs 1995; 50: 176-196.
5. Pozniak A, Yoganathan K, McNicol S, et al. Improved bioavailability of atovaquone from a new suspension formulation in healthy volunteers and HIV infected patients [abstract]. 9th International Conference on AIDS, Berlin, June 1992.
6. Araujo FA, Huskinson J, Remington JS. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicroh Agents Chemother 1991; 35: 293-299.
7. Kovacs JA. Efficacy of atovaquone in the treatment of toxoplasmosis in patients with AIDS. Lancet 1992; 340: 637-638.
8. Perucca E, Richens A. Drug interactions with phenytoin. Drugs 1981; 21: 120-137.
9. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokin 1979; 4: 153-169.
10. Lee BL, Taüber MG, Sadler B, et al. Atovaquone inhibits the glucuronidation and increases the serum concentrations of zidovudine [abstract]. In 34th Interscience Conference on Antimicrobial Agents and Chemotherapy ( 1994): 81.
11. DeAngelis DV, Long JD, Kanics LL, Woolley JL. High performance liquid chromatographic assay for the measurement of atovaquone in plasma. J Chromatogr 1994; 652: 211-219.
12. Rowland M, Tozer TN. Clinical pharmacokinetics: Concepts and applications. 2nd edition, 1989; Lea & Febiger, Philadelphia and London.